Pharmacogenetics implementation in the clinics: information and guidelines for germline variants
Keywords: 
PharmGKB
Oncology
Guidelines
Clinical implementation
Polymorphisms
Pharmacogenetic
Issue Date: 
2019
ISSN: 
2578-532X
Note: 
This article is licensed under a Creative Commons Attribution 4.0 International License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, sharing, adaptation, distribution and reproduction in any medium or format, for any purpose, even commercially, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license,
Citation: 
Olivera, G.; Sendra, L.; Herrero, M. J.; et al. "Pharmacogenetics implementation in the clinics: information and guidelines for germline variants". Cancer drug resistance. 2 (1), 2019, 53 - 68
Abstract
The aim of this work was to supply an overview of the germline Pharmacogenetics that can be already implemented in the oncology clinical practice. An explanation of the three pillars considered necessary for determining which genetic polymorphisms should be used has been provided. These are PharmGKB single nucleotide polymorphism (SNP)-Drug Clinical Annotations with levels of evidence 1 or 2; the genetic information provided in the drug labels by the drug regulatory main agencies (Food and Drug Administration and European Medicines Agency, mainly); and the guidelines elaborated by international expert consortia (mainly Clinical Pharmacogenetics Implementation Consortium and Dutch Pharmacogenetics Working Group). A summary of the relevant SNPs and the recommendations on how to apply their results has also been compiled.

Files in This Item:
Thumbnail
File
pdf.pdf
Description
Size
547.71 kB
Format
Adobe PDF


Statistics and impact
0 citas en
0 citas en

Items in Dadun are protected by copyright, with all rights reserved, unless otherwise indicated.